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Abstract
Background: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAFV600
mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical
trials are in progress using MEK inhibitors following disease progression in patients receiving BRAF inhibitors. However, the
PI3K/AKT pathway can also induce resistance to the inhibitors of MAPK pathway.
Methodology/Principal Findings: The sensitivity to vemurafenib or the MEK inhibitor AZD6244 was tested in sensitive and
resistant human melanoma cell lines exploring differences in activation-associated phosphorylation levels of major signaling
molecules, leading to the testing of co-inhibition of the AKT/mTOR pathway genetically and pharmacologically. There was a
high degree of cross-resistance to vemurafenib and AZD6244, except in two vemurafenib-resistant cell lines that acquired a
secondary mutation in NRAS. In other cell lines, acquired resistance to both drugs was associated with persistence or
increase in activity of AKT pathway. siRNA-mediated gene silencing and combination therapy with an AKT inhibitor or
rapamycin partially or completely reversed the resistance.
Conclusions/Significance: Primary and acquired resistance to vemurafenib in these in vitro models results in frequent cross
resistance to MEK inhibitors, except when the resistance is the result of a secondary NRAS mutation. Resistance to BRAF or
MEK inhibitors is associated with the induction or persistence of activity within the AKT pathway in the presence of these
drugs. This resistance can be potentially reversed by the combination of a RAF or MEK inhibitor with an AKT or mTOR
inhibitor. These combinations should be available for clinical testing in patients progressing on BRAF inhibitors.
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Introduction
BRAFV600E is a dominant activating mutation in melanoma
resulting in a constitutive activation of the mitogen-activated
protein kinase (MAPK) pathway and uncontrolled cell growth
[1,2]. Its role as a driver mutation for this cancer is validated by
the high rate of tumor responses in patients with BRAFV600E
mutant metastatic melanoma treated with the type I RAF inhibitor
vemurafenib (previously know as PLX4032 or RG7204) [3]. These
clinical results with vemurafenib highlight that, despite the
presence of multiple other genomic alterations in advanced
melanoma, metastatic lesions with a BRAFV600E mutation have
all the features of oncogene addiction [4]. However, it is likely that,
after the initial tumor response, secondary alterations in
melanoma cells may contribute to the development of acquired
resistance to vemurafenib and other type I RAF inhibitors with
specific antitumor activity against mutated BRAF, such as
dabrafenib (previously GSK2118436) [5].
Similar to other cancers, melanomas have frequent alterations
in the phosphatidylinositol 3-kinases (PI3K) and v-akt murine
thymoma viral oncogene homolog 1 (AKT) pathway, another key
signal transduction pathway governing cell growth and survival.
The most common alterations are genomic or functional loss of
PTEN and amplification and point mutations in AKT [2].
Multiple pathways are activated downstream of AKT, the major
one going through the mammalian target of rapamycin (mTOR)
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and its downstream effector ribosomal protein S6 kinase, 70-KD,
1 (RPS6KB1 or herein as p70 S6K1). It has been postulated that
cells with mutations in BRAF may require co-operating alterations
in PTEN or AKT to activate both main signal transduction
pathways [6]. This is opposed to melanomas with NRAS
mutations, since RAS mutations can provide oncogenic signal
through both the MAPK and the PI3K/AKT pathways.
Therefore, approaches to simultaneously inhibit both the MAPK
and PI3K/AKT pathways have been proposed in melanoma [7].
The advent of highly specific inhibitors for oncogenic BRAF with
robust activity in BRAFV600E mutant melanoma [3,8,9,10] and the
clinical development of specific inhibitors of PI3K, AKT and
mTOR, provide the tools to translate these concepts into the
clinic.
Analysis of clinical samples provided evidence that the
antitumor activity of vemurafenib is mediated by inhibition of
ERK signaling [8]. In addition, preclinical data had suggested that
BRAFV600E mutant melanomas may continue to depend on the
MAPK even after progressing on BRAF inhibitors, through the
reactivation of phosphorylated ERK in resistant cells [11,12].
Since MEK1/2 is the required signaling node between RAF and
ERK, it had been postulated that a maintained dependence on the
MAPK pathway in RAF inhibitor-resistant cells could be treated
with specific MEK inhibitors. Based on these observations, clinical
trials are underway to block MEK in patients whose BRAFV600E
mutant melanoma had a response but then progressed on BRAF
inhibitors like vemurafenib or dabrafenib.
In this study we first tested the concept of treating with a MEK
inhibitor upon progression on a BRAF inhibitor in selected
melanoma cell lines that encompassed cell lines with primarily
resistance to vemurafenib, those with acquired resistance to
vemurafenib after in vitro exposure, and those established from
patient-derived biopsies progressing after vemurafenib. Recent
studies have shown that in addition to the dependence on MAPK
pathway, over expression of receptors such as the platelet-derived
growth factor beta (PDGFRb) or the insulin growth factor-1
receptor (IGF-1R), which are upstream of PI3K/AKT pathway,
may play important roles in the resistance to BRAF inhibitors
[13,14]. Therefore, we also investigated the activity of the AKT
pathway and its possible effect on the resistance of melanoma cells
to inhibitors of MAPK pathway. We also examined whether the
induction of AKT signaling by inhibitors of MAPK pathway may
in part be caused by the activation of the feedback mechanisms
originating from the downstream factors in AKT pathway. Our
results suggest that most BRAFV600E mutant melanomas not
responding to vemurafenib are also cross-resistant to single agent
MEK inhibitors, but co-targeting of the AKT/mTOR pathway
provides means of treating most of these resistant cells.
Materials and Methods
Reagents and cell lines
Vemurafenib (also known as PLX4032, RG7204 or
RO5185426) was obtained under a materials transfer agreement
(MTA) with Plexxikon (Berkeley, CA) and Roche (Nutley, NJ). It
was dissolved in DMSO (Fisher Scientific, Morristown, NJ) to a
stock concentration of 100 mM. AZD6244 was purchased from
Selleck Chemicals (Houston, TX) and dissolved in DMSO to a
100 mM stock. The isozyme-selective AKTi VIII (AKTi,
Calbiochem, Cambridge, MA) was dissolved in DMSO to a stock
concentration of 10 mM. Rapamycin in EtOH (Calbiochem) was
used for the drug combination experiments at the noted
concentrations. Human melanoma cell lines (M series) were
established from patient’s biopsies under UCLA IRB approval
#02-08-067 as previously described [15]. Cells were cultured in
RPMI 1640 with L-glutamine (Mediatech Inc., Manassas, VA)
containing 10% (unless noted, all percentages represent volume to
volume) fetal bovine serum (FBS, Omega Scientific, Tarzana, CA)
and 1% penicillin, streptomycin and amphotericin B (Omega
Scientific). All cell lines were mycoplasma free when periodically
tested using the Mycoalert assay (Lonza, Rockland, ME).
Establishment of vemurafenib-resistant cell lines derived
from patient’s tumor biopsies
Four cell lines were derived from patients participating in the
phase I (NCT00405587) or phase II (NCT00949702) clinical trials
with vemurafenib as previously described [13]. These cell lines
were obtained after written informed consent under the UCLA
Institutional Review Board approval IRB#02-08-067. This same
IRB approval covered the establishment and use of other cell lines
included in this research. M370, M376 and M395 were derived
from tumor biopsies of metastatic melanoma lesions progressing
after an initial objective response to vemurafenib treatment. M380
was derived from a melanoma metastasis primarily resistant to
vemurafenib from the start of treatment with the drug. In brief,
tumor biopsies were minced and enzymatically treated with 0.1%
type I collagenase (Sigma Immuno Chemicals, Fluka Chemie,
Buchs, Switzerland) and 0.02% DNase (Boehringer Mannheim,
Mannheim, Germany) in complete tissue culture medium for
2 hours. After centrifugation, cells were resuspended in RPMI
1640 with L-glutamine (Mediatech Inc., Manassas, VA) containing
20% FBS, and 1% penicillin, streptomycin and amphotericin B,
and incubated at 37uC in a 5% CO2- and water-saturated
incubator. The medium was changed when most cells had
attached and cell cultures were then propagated and passaged in
vitro as needed. These in vivo resistant cultures were not routinely
selected with constant exposure to vemurafenib.
In vitro acquired vemurafenib resistance
To generate cell lines with in vitro acquired resistance,
BRAFV600E mutant melanoma cell lines with in vitro sensitivity to
vemurafenib were plated in T25 flasks and treated with their
respective IC50 of vemurafenib as described previously [13]. The
vemurafenib concentration was then either increased or remained
the same depending on the previous viability count, for 120-hour
periods, until a subline grew progressively in the presence of
vemurafenib above the IC50 for the parental cell line. The subline
was labeled as the parental cell line followed by ‘‘AR’’ for acquired
resistance.
Cell proliferation and viability assays
Melanoma cell lines were treated in triplicate with vemurafenib,
AZD6244, AKTi or rapamycin (or the combinations) and parallel
vehicle control in the given concentrations for 72 hours. Cell
viability was measured using a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium (MTS)-based colorimetric cell proliferation
assay (Promega, Madison, WI) as previously described [15]. Each
experiment has been repeated at least twice and the most
reproducible study is presented.
Oncogene characterization of cell lines
Information for the oncogenic characterization of the cell lines
tested herein was based mainly on data we have previously reported
[13,15]. The additional analysis of gene copy changes based on
DNA extracted from melanoma cell lines hybridized onto
HumanOmni1-Quad_v1-0_B (Illumina Inc., San Diego, CA).
Cross-Resistance to BRAF and MEK Inhibitors
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siRNA transfection
Cell lines were transfected with the gene-specific or no target
control siRNAs (Dharmacon, Lafayette, CO). To perform the
transfection, LipofectamineTM RNAiMAX reagent (Invitrogen,
Carlsbad, CA) was used according to the Reverse Transfection
method described by the manufacturer. In brief, 40 pmol of each
siRNA was diluted separately into 250 ml of serum free phenol red
free RPMI 1640. To each diluted siRNA, 3 ml of LipofectamineTM
RNAiMAX was added. Each transfecting mixture was added to
1.86105 cells suspended in 1.25 ml of the culturing media. Then,
each sample was plated for protein isolation after 72 hours or
RNA isolation after 48 hours or for the drug treatment after
24 hours and assessment of proliferation rate after 120 hours.
Western blotting
Western blotting was performed as previously described [16].
Primary antibodies included p-AKT Ser473 and Thr308, AKT, p-
S6K1 Thr389, S6K1, p-S6 Ser235/236, p-4EBP-1, S6, p-ERK
Thr204/205, ERK, pMEK Ser217/221, MEK, 4EBP-1, cleaved
caspase-3 and beta-actin (all from Cell Signaling Technology,
Danvers, MA). The immunoreactivity was visualized by use of an
ECL-Plus kit (Amersham Biosciences Co, Piscataway, NJ) and
scanning of the blots by the Typhoon scanner (Amersham
Biosciences Co, Piscataway, NJ).
Apoptosis assay
To perform the apoptosis assay cells were treated with the
solvent (DMSO) or 2 mM of vemurafenib, AZD6244, AKTi or
10 nM of rapamycin or combination of these compounds. After
48 hours of treatment, protein lysated were prepared from each
condition and analyzed by Western blotting method for the
detection of cleaved caspase-3.
RT-PCR for detection of S6K2 mRNA level. RT-PCR
assay was used to investigate the efficiency of ribosomal protein S6
kinase, 2 (RPS6KB2 or here in S6K2) knockdown by siRNA
cocktail at mRNA level. M238 and M238AR2 cell lines were
transfected with a combination of 25 pmol of S6K2 siRNA plus
25 pmol of S6K1 siRNA or with 50 pmol of control SiRNA (as
described in the above). Cells were harvested after 48 hours and
total RNA was isolated by using RiboPureTM Kit (Ambion,
Austin, TX). RT-PCR assays were performed on 350 ng of total
RNA isolated from each sample by using SuperScript III One-
Step RT-PCR System with PlatinumH Taq kit (Invitrogen,
Carlsbad, CA). Specific S6K2 set of primers (Forward
59CTGAGCGGAACATTCTAGAGT 39 and Reverse 59-
AAGTCGGTCAGTTTGATGTGG-39) were used to amplify a
cDNA fragment of,300 base pares. The primers span the sides of
an intron and do not amplify the genomic DNA. As a control for
the integrity and level of RNA, GAPDH was amplified by specific
Forward (59-GTCAACGGATTTGGTCGTATT 39) and Reverse
(59-AGTCTTCTGGGTGGCAGTGAT 39) primer set. RT-PCR
cycles were as follows: Reverse transcription at 50uC for
30 minute, 95uC for 2 minutes, 27 cycles of 94uC (15 Sec),
56.5uC (30 Sec), 68uC (30 Sec), and 68uC for 5 minutes. The
samples were analyzed on 1.5% agarose gel.
Statistical analysis
To determine synergistic, additive, or antagonistic effects of the
drug combinations, we used the combination index method of
Chou and Talalay [17] using the CalcuSyn software (version 2.0
Biosoft, Cambridge, UK). This method takes into account both
potency [median dose (Dm) or IC50] and the shape of the dose-
effect curve (the m value) to calculate the combination index (CI).
A CI equal to 1 indicates an additive effect; a CI less than 1
indicates synergy. With the use of CalcuSyn software, synergy is
further refined as synergism (CI= 0.3–0.7), strong synergism
(CI= 0.1–0.3), and very strong synergism (CI,0.1).
Results
Frequent cross-resistance to vemurafenib and AZD6244
We analyzed if melanoma cell lines resistant to vemurafenib
would be sensitive to the MEK inhibitor AZD6244 using MTS
assays (Figure 1 and Figure S1). Cell lines with IC50 s above 10 mM
for each agent were considered resistant. M229, M238 and M249
are three BRAFV600E mutant parental cell lines sensitive to
vemurafenib [15]. These three cell lines also demonstrated high
sensitivity to AZD6244. The corresponding sublines with acquired
resistance after continuous in vitro culture in increasing concentra-
tions of vemurafenib also exhibited a complete (M229-AR9,
M238-AR2) or a partial (M249-AR4) resistance to single agent
AZD6244. The other three cell lines (M370, M376, M395)
obtained from metastatic melanoma lesions surgically resected
from patients progressing on vemurafenib had different sensitiv-
ities to both agents. M370 was established from an intra-cardiac
mass which developed six months after starting on vemurafenib. It
corresponds to the sample labeled as Pt48 R in ref. [13]. This cell
line maintained partial in vitro sensitivity to vemurafenib but was
resistant to AZD6244. M376 was established from a lymph node
metastatic lesion that partially regressed on vemurafenib but
increased in size 10 months after starting the therapy. It
corresponds to the sample labeled as Pt55 R in ref. [13]. This
cell line was markedly resistant to vemurafenib but was sensitive to
AZD6244. M395 was established from an adrenal metastasis that
had partially regressed on vemurafenib therapy during 5 months,
but then slowly increased in size. Surprisingly, this cell line
maintained in vitro sensitivity to both vemurafenib and AZD6244.
For these studies, the cell lines obtained from patients treated with
vemurafenib had been cultured ex vivo without the presence of low
dose vemurafenib for several passages, which is different from
studies performed by Nazarian et al. [13]. M233 and M263 are
previously established BRAFV600E mutant cell lines with primary
resistance to vemurafenib [15]. They also demonstrated primary
resistance to AZD6244. M380 is a cell line established from a
baseline subcutaneous metastasis in a patient with metastatic
melanoma who had progression with vemurafenib treatment at
restaging scans 6 weeks after the initiation of treatment with
vemurafenib. The biopsied lesion transiently decreased in size for
two weeks while on vemurafenib but it then rapidly progressed.
This cell line was partially sensitive to vemurafenib ex vivo but
completely resistant to AZD6244. Thus, with the exception of
M249-AR4 and M376, BRAFV600E mutant melanoma cell lines
resistant to vemurafenib have cross resistance to the MEK
inhibitor AZD6244.
Acquired resistance to vemurafenib mediated by a
secondary NRAS mutation leads to sensitivity to a MEK
inhibitor
We explored the oncogenic alterations in this panel of cell lines
using targeted oncogene sequencing and SNP arrays (Table 1 and
references [13,15]). The presence of a secondary mutation in
NRASQ61K, in addition to the BRAFV600E mutation, in the in vitro
acquired resistant cell line M249-AR4 and in the patient-derived
acquired resistant cell line M376, was associated with resistance to
vemurafenib but sensitivity to AZD6244, corroborating the earlier
study [13]. Upon treatment of M376 with vemurafenib (24 hours),
despite a partial decrease in p-MEK, no obvious decrease in p-
Cross-Resistance to BRAF and MEK Inhibitors
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ERK1/2 or in factors downstream of AKT was observed. On the
contrary, AZD6244 caused the accumulation of p-MEK, as well as
decreases in p-ERK1/2 and p-S6 (Figure 2). These findings
indicate that vemurafenib fails to inhibit the NRASQ61K-induced
signaling while the MEK inhibitor AZD6244 blocks the pathway,
and consequently inhibits the cell proliferation in these cell lines.
Secondary mutations in BRAF, KRAS, NRAS or HRAS were not
noted in any other cell line [13]. These data provide strong
indication that in BRAF mutant cells that have a secondary NRAS
mutation, or perhaps other mechanisms of acquired resistance that
reactivate MEK, addition of a MEK inhibitor can result in
secondary responses. Therefore, we focused mostly on the non-
NRAS secondary mutation cells since it was not clear what
signaling pathway should be blocked to control them. We
continued by studying MAPK and alternative signaling through
the PI3K/AKT pathway on non-NRAS secondary mutated
resistant cell lines.
Drug induced alterations of MAPK signaling and
differential modulation of the AKT pathway in
vemurafenib-sensitive and -resistant cell lines
We selected two pairs of parental and their in vitro acquired
resistant sublines and four of the patient-derived cell lines to
explore signaling pathways that may be differentially modulated
upon treatment with the RAF or MEK inhibitors for 24 hours
(Figure 2). Vemurafinib treatment of parental cell lines caused a
decrease in the level of p-MEK in a dose dependent manner.
However, this decrease was less extensive in the highly resistant
cell lines (M238-AR2 and M229-AR9). Similarly, in M238-AR2
and M229-AR9, vemurafenib was inefficient in causing a decrease
in the p-ERK1/2 levels when analyzed at the 24 hour time point
(note that the timing of these studies analyzing p-ERK is later than
the evidence of maintained ability to inhibit p-ERK at earlier time
points in our prior studies [13], suggesting p-ERK recovery after
the initial suppression). On the contrary, AZD6244 treatment
induced higher levels of p-MEK in the cell lines that showed in vitro
resistance to vemurafenib (M229-AR9, M238-AR2, M370, and
M380), as well as in M376 which was sensitive. p-ERK1/2 levels
were lower in all the AZD6244 treated samples regardless of their
sensitivity to either one of the drugs.
The differences in p-AKT/p-p70 S6K1/p-S6 pathways were
more pronounced between sensitive and resistant cell lines.
Vemurafinib and AZD6244 induced similar changes in p-AKT
levels. However, it seemed that these changes were cell line-
dependent, showing simultaneous increases in p-AKT T308 and
S473 (suggesting feedback) in the resistant cell lines M238-AR2,
M229-AR9 and M370, while there were no obvious changes in
M395, and decreases in both p-AKT levels in M238 and M380.
Thus, none of the cell lines highly resistant to vemurafenib showed
decreases in one or both p-AKT levels after the exposure to the
drugs. In fact, vemurafenib (and to a lesser extent AZD6244)
treatment of vemurafenib-acquired resistant cell lines consistently
increased p-AKT levels, with the notable exception of the N-RAS
mutated line, M376. Exposure of sensitive cell lines, M229 and
M238, to even low concentrations of the drugs caused drastic
decreases in their p-p70 S6K1 and p-S6 levels. However,
particularly at lower concentrations of the drugs, there was less
or no effect on p-p70 S6K1 levels in the in vitro acquired resistant
cells M238-AR2 and M229-AR9, and the patient-derived resistant
cell lines. Both vemurafenib and AZD6244 caused decreases in p-
S6 levels in sensitive cell lines but almost no clear changes in the
their resistant sublines. However, it seemed that the decrease in p-
S6 was not associated with the pattern of response to the drugs
except when accompanied by a decrease in p-p70 S6K1. 4-EBP-1
is another important factor downstream of AKT/mTOR pathway
that has been reported to link this pathway to the MAPK pathway
[18]. Only the sensitive cell lines M238 and M229 showed
detectable deceases in levels of p-4-EBP-1 after exposure to
vemurafenib or AZD6244. Altogether, these data suggest that in
cell lines with resistance to vemurafenib, regardless of the presence
or absence of a secondary NRAS mutation, this agent at least
partially maintained the ability to inhibit phosphorylation of
MEK. The unexpected effect of MAPK (in particular BRAF)
inhibition on p-AKT increase in non-NRAS mutated, vemur-
afenib-acquired resistant lines suggested crosstalk between AKT
and the MAPK pathway and points to potential therapeutic
opportunities in the AKT-mTOR pathway.
Figure 1. IC50 values of BRAF
V600E mutated melanoma cells
after exposure to vemurafenib (a) or AZD6244 (b). The cells were
treated for 120 hours (vemurafenib) or 72 hours (AZD6244). Cell
viability was determined by MTS colorimetric assay. IC50 values (x-axis)
are expressed in mM for vemurafenib or AZD6244. Black columns:
Parental cell lines sensitive to vemurafenib. Gray columns: Sublines with
in vitro acquired resistance to vemurafenib. Gray columns filled with
coarse striped pattern: Cell lines derived from progressive lesions in
patients treated with vemurafenib. White columns: vemurafenib
primarily resistant cell lines. White column filled with coarse striped
pattern: Cell line derived at baseline from a patient who did not
respond clinically to vemurafenib.
doi:10.1371/journal.pone.0028973.g001
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Reversal of the pattern of resistance with genetic
silencing of RICTOR or S6K1 and 2
mTORC complexes have been described as the central node for
regulation of growth and metabolism. RICTOR is one of the
proteins in mTORC2 complex that phosphorylates AKT at Ser473
through a feedback mechanism. This phosphorylation is necessary
for the complete activation of AKT. p70 S6K1 is one of the key
factors downstream of mTOR that phosphorylate and induces S6
activity. Given the pattern of p-AKT induction primarily in the
non-NRAS mutant acquired resistant melanoma cell lines we
focused on the effects of inhibiting the mTORC complexes or p70
S6K1. In M238-AR2 and its parental cell line, transient knockdown
of each target was achieved by transfection of cells with the target
specific siRNAs pool that resulted in a reproducible knockdown of
at least 70% at protein levels (Figure 3a). A highly homologous gene
to p70 S6K1 is S6K2 which has been suggested to compensate for
the lack of p70 S6K1 function in animal knockout studies [19].
Therefore, in order to avoid the redundant functional effect of
S6K2 in the context of p70 S6K1 knockdown, pooled siRNAs for
the knockdown of S6K2 was mixed with those for the knockdown of
S6K1. The knockdown of S6K2 was detected by RT-PCR using
trans-intron specific primers for this gene (Figure 3a). The
knockdown of S6K1 and 2 caused a decrease in phosphorylation
of p-S6 in all cases. Similar to previous experiments, in M238
parental cell line treatment with vemurafenib or AZD6244 alone
was sufficient to decrease the p-S6 levels visibly. Interestingly, in
M238-AR2, such a decrease in p-S6 level could only be achieved if
the knockdown of S6K1 and 2 was combined with either
vemurafenib or AZD6244 treatment (Figure 3a). These results
suggest that in this resistant cells, S6 is a cross-talk point between
MAPK and AKT pathways and therefore inhibition of both
pathways is required to down-regulate the activity of this protein. In
the growth assays, genetic silencing of both S6K1 and S6K2 caused
a significant decrease in the growth rates of the cells and also
reversed the growth inducing effect of both drugs which is observed
in the resistant cell line M238-AR2 (Figure 3b and 3c).
As it was expected, knockdown of RICTOR caused an evident
decrease in phosphorylation of p-AKT at Ser473. Interestingly,
knockdown of RICTOR also caused a clear decrease in
phosphorylation of 4-EBP-1 particularly in the presence of
vemurafenib or AZD6244, and also a detectable decrease in p-
S6 level only in M238-AR2 treated with the agents (Figure 3a).
Table 1. Cell line characterization.
Cell Line Vemurafinib sensitive/resistance origin Main oncogenic events
M229 In vitro naturally sensitive BRAFV600E homozygous
AKT1 amplification
PTEN heterozygous deletion
M229-AR9 In vitro acquired resistance BRAFV600E homozygous
AKT1 amplification
PTEN heterozygous deletion
M238 In vitro naturally sensitive BRAFV600E heterozygous
PTEN heterozygous deletion
CDKN2A homozygous deletion
M238-AR2 In vitro acquired resistance BRAFV600E heterozygous
PTEN heterozygous deletion
CDKN2A homozygous deletion
M249 In vitro naturally sensitive BRAFV600E heterozygous
PTEN homozygous deletion
M249-AR4 In vitro acquired resistance BRAFV600E heterozygous
NRASQ61K heterozygous
PTEN homozygous deletion
M370 Patient-derived from a cardiac mass with acquired resistance BRAFV600E heterozygous
M376 Patient-derived from a nodal metastasis with acquired resistance BRAFV600E heterozygous
NRASQ61K heterozygous
PTEN heterozygous deletion
M380 Patient-derived from a subcutaneous mass with natural resistance BRAFV600E heterozygous
CDKN2A homozygous deletion
M395 Patient-derived from an adrenal mass with acquired resistance BRAFV600E homozygous
CDKN2A homozygous deletion
M233 In vitro naturally resistant BRAFV600E heterozygous
AKT1 amplification
PTEN homozygous deletion
M244 In vitro naturally resistant NRASQ61K heterozygous
M263 In vitro naturally resistant BRAFV600E heterozygous
doi:10.1371/journal.pone.0028973.t001
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These results suggest that in melanoma cells resistant to inhibitors
of MAPK pathway, 4-EBP-1 is a cross-talk point between MAPK
and AKT pathways. Therefore blocking of both pathways is
necessary to down regulate activities of proteins downstream of
AKT pathway. In growth inhibition assays, genetic silencing of
RICTOR significantly decreased the growth rates and reversed
the growth inducing effect of vemurafenib and AZD6244 in the
resistant cell line (Figure 3b and 3c). These findings suggest that
the mTORC2 feedback that phosphorylates AKT may play an
important role in maintenance or induction of cell growth and
therefore causing the resistance to MAPK pathway inhibitors.
RAPTOR is one of the main proteins in mTORC1 complex. In
our experiments, knockdown of RAPTOR caused detectable
decreases in phosphorylation of p-p70 S6K1 in both parental and
resistant cell line. However, knockdown of RAPTOR in these cell
lines caused no detectable decrease in p-S6 level (Figure S2a).
Knockdown of RAPTOR decreased the growth rate of both cell
lines. However, it could not prevent the growth-inducing effect of
vemurafenib and AZD6244 in the M238-AR2 resistant cell line,
which can be observed even at up to 1 mM level of these drugs (Figure
S2b). This phenomena in our RAPTOR knockdown cells can be due
to the lack of decrease in phosphorylation of S6 in combination with
the described feedback mechanism that is initiated by the mTORC1
inhibition and causing over activity of mTORC2 and consequently
inducing higher phosphorylation of AKT Ser473 [20].
Frequent reversal of resistance to vemurafenib or
AZD6244 with concomitant inhibition of AKT or mTOR
To examine clinically-relevant means of addressing primary or
acquired resistance to single agent MAPK inhibitors we tested the
Figure 2. Effects of vemurafenib or AZD6244 on MAPK and PI3K/AKT pathways in BRAFV600E mutated cell lines. Western blot analysis
of phosphorylated and the total amount of key proteins in the MAPK and PI3K/AKT pathways after 24 hours of exposure to the solvent (DMSO), or
various concentrations of the BRAF inhibitor vemurafenib or the MEK inhibitor AZD6244. The vemurafenib-sensitive M238 and M229 cell lines and the
vemurafenib in vitro acquired resistant sublines M238-AR2 and M229-AR9 were cultured at different concentrations of vemurafenib (a) or AZD6244
(b). The vemurafenib-resistant cell lines derived from patient’s tumor biopsies M370, M376, M395 and M380 were cultured in different concentrations
of vemurafenib (c) or AZD6244 (d). p70 and p-p70 S6K in this figure are referred to S6K1 and phosphorylated form of S6K1, respectively.
doi:10.1371/journal.pone.0028973.g002
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addition of an AKT1/2 or a mTORC1 pharmacological inhibitor.
All cell lines were resistant to single agent AKT inhibitor (AKTi)
or rapamycin (Figures 4 and 5). Among the parental and acquired
resistance subline pairs, resistance to vemurafenib in M229-AR9
was partially reversed with the addition of rapamycin but not with
the AKTi, and resistance to AZD6244 could not be reversed with
either agent (Figure 4). In M238-AR2, resistance to vemurafenib
and AZD6244 was better reversed with the AKTi compared to
rapamycin which also recapitulates our results on effects of
RICTOR versus RAPTOR knockdowns on resistance (Figure 3c
and figure S2c). For M249-AR4 both AKTi and rapamycin
provided strong synergistic effects with either vemurafenib or
Figure 3. Effects of both S6K1 and S6K2 or RICTOR siRNA knockdown combined with vemurafenib or AZD6244. The efficiency of
siRNA knockdowns and their effects on downstream signaling determined by Western blot analysis of protein lysates or in the cases of S6K2 and
GAPDH by RT-PCR of isolated mRNA (a). M238 parental (b) and M238-AR2 resistant subline (c) were transfected with siRNAs for either RICTOR or
combined S6K1 & 2 or non target control siRNAs and cultured in increasing concentrations of vemurafenib or AZD6244. The effects of knockdowns
on resistance and growth inhibition were analyzed after 120 hours by an MTS assay. D in each graph refers to the un-transfected untreated cells and
is used as the 100% reference point for all the conditions in each graph.
doi:10.1371/journal.pone.0028973.g003
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AZD6244. The primarily resistant established cell lines continued
to display cross-resistance to vemurafenib and AZD6244 in most
cases, except for the addition of AKTi to AZD6244 (but not
vemurafenib) in M233 (Figure 5). Among the patient-derived cell
lines there was evidence of high synergy with the addition of the
AKTi or rapamycin to either vemurafenib or AZD6244 in all
instances. This includes M376, which is highly sensitive to single
agent AZD6244, and the addition of AKTi or rapamycin resulted
in further synergistic inhibitory effects.
To investigate the effect of each one of these drugs and their
combinations in induction of apoptosis in in vitro sensitive/adaptive
resistant pair cell lines, we detected cleaved caspase-3 (CC3) levels
by Western blotting method (Figure S3). In all three parental
sensitive cell lines (M229, M238, M249) significant amount of
CC3 was detected after 48 hours of treatment with vemurafenib,
AZD6244 or their combinations with rapamycin and AKTi. As it
was expected, M249-AR4 with a secondary mutation in NRAS
showed no detectable CC3 after treatment with vemurafenib,
Figure 4. AKTi or rapamycin combined with vemurafenib or AZD6244 in vemurafenib-sensitive and -acquired resistant cell lines.
IC50 of the parental cell lines M229, M238 and M249, and the acquired resistance sublines M229-AR9, M238-AR2 and M249-AR4 determined in an MTS
assay using single agent AKTi, rapamycin, vemurafenib or AZD6244, or in combinations. Vemurafinib or AZD6244 in combination with AKTi were
tested at 1:1 ratios at concentrations of 0.1, 1 or 5 mM, or with rapamycin at 0.1, 1 and 5 nM. For the combination studies the IC50 bar represents
either vemurafenib or AZD6244 used in the combination. The combination indexes (CI) were calculated by the Chou-Talalal method and denoted
over each column where a synergistic (CI,1) effect was noted. There are three CIs per condition reflective of the three different concentrations
tested, 0.1; 1 and 5 for each drug at 1:1 ratio (mM for PLX; AZD and AKTi; nM for rapamycin).
doi:10.1371/journal.pone.0028973.g004
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rapamycin, AKTi and their combinations. However, AZD6244
and its combination with rapamycin and AKTi induced noticeable
levels of CC3. In the cases of M238-AR2 and M229-AR9, only
low levels of CC3 was detectable after treatment with AZD6244
and its combination with rapamycin and AKTi.
Discussion
The work presented herein provides evidence of frequent cross-
resistance to the BRAF inhibitor vemurafenib and the MEK
inhibitor AZD6244 in cell lines with primary or acquired
resistance to vemurafenib, with frequent reversal of the acquired
resistance by the addition of inhibitors of the AKT/mTOR
pathway. In this study only cell lines with a secondary NRAS
mutation, that are sensitive to MEK inhibitor, were the exceptions
to the cross-resistance to BRAF and MEK inhibitors. The cross-
resistance between the BRAF and MEK inhibitors is rather
surprising given the exquisite dependence that BRAFV600E mutant
melanomas have demonstrated on the MAPK pathway. In paired
biopsies of patients treated with vemurafenib this agent demon-
strated a dose-dependent inhibition of p-ERK, suggesting that the
activity of this agent as inhibitor of oncogenic BRAF relies on
efficient inhibition of MAPK pathway signaling [8]. The
development of in vitro acquired resistance to PLX4720, an
analogue of vemurafenib, has been linked to the re-activation of p-
ERK [12]. In addition, acquired resistance to a different BRAF
inhibitor, AZ628, was associated with alternate signaling from
BRAF to CRAF again resulting in the re-activation of p-ERK
[11]. Combined, these data had suggested that further inhibition
of the MAPK pathway with a MEK inhibitor may be a way to
treat acquired resistance to the BRAF inhibitor. In fact, this
concept has been taken into the clinic with ongoing clinical trials,
but our data predicts that sequential single agent treatment with a
MEK inhibitor after developing acquired resistance to a BRAF
inhibitor will only work (partially) in a subset of cases with
secondary NRAS mutations.
As the molecular mechanisms of primary and acquired
resistance to vemurafenib are being studied [13,14,21,22] it will
Figure 5. AKTi or rapamycin combined with vemurafenib or AZD6244 in patient-derived vemurafenib-primary/-acquired resistant
cell lines. IC50 of the primarily resistant cell lines M233, M244 and M263, and the patient-derived acquired resistance cell lines M370, M376 and the
primarily resistant patient-derived cell line M380 determined by an MTS assay and analyzed for synergistic effects as described in Figure 4.
doi:10.1371/journal.pone.0028973.g005
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be important to tailor the treatments to be added or sequentially
tested in patients progressing on this therapy. It is becoming clear
that resistance to BRAF inhibitors will not follow the pathway of
resistance of chronic myelogenous leukemia (CML) to imatinib,
where secondary mutations in the abl kinase are the main
mechanism of resistance [23]. The study of resistance mechanisms
in the sublines with in vitro acquired resistance to vemurafenib and
patient-derived resistant cell lines included in this and other studies
suggest three main mechanisms of acquired resistance, the
upregulation of the receptor tyrosine kinases such as PDGFR1b
[13] or IGF1R [14], increased expression of the cancer Osaka
thyroid (COT, also known as MAP3K8) kinase [21], or secondary
mutations in NRAS [13] or MEK [22]. Secondary mutation in
NRAS or MEK, or upregulation of COT suggests acquired
resistance mechanisms that maintain dependence on the MAPK
pathway. In our studies, two vemurafenib-resistant cell lines with
an acquired NRASQ61k mutation secondary to their pre-existing
BRAFV600E mutation exhibited some sensitivity to a sequential
treatment with a MEK inhibitor. Interestingly, these two cell lines
with the secondary NRAS mutation also showed sensitivity to the
combinations of drugs inhibiting both AKT and MAPK pathways.
This may be due to a possible cross talk between mutated NRAS
and AKT pathway. Possibility of such a cross talk holds clinical
and scientific importance and would be interesting to be
investigated in the future studies. Meanwhile, all other cell lines
displayed resistance to the sequential treatment with the MEK
inhibitor if they were resistant to vemurafenib. In this group of
resistant cell lines, most have the PDGFRb-mediated mechanism
of acquired resistance [13]. This information suggests that the
elucidation of the specific mechanisms of resistance to vemurafenib
points out to different therapies to be added or used sequentially
with BRAF inhibitors.
A recent study on resistance to an analog of vemurafinib,
PLX4720, suggested that only in cell lines with PTEN deletion p-
AKT is induced by this BRAF inhibitor, and lack of PTEN may
play a role in preventing apoptosis of melanoma cell treated with
this compound [24]. However, in our study we found that the
PTEN null cell line M249 was very sensitive to both vemurafenib
and AZD6244, which may be an outlier compared to prior reported
data [24]. Interestingly, by continuous exposure of this BRAFV600E
mutant/PTEN null cell line to vemurafenib an acquired resistant
cell line that was mediated by a secondary mutation in NRAS
causing the resistance through the reactivation of the MAPK
pathway. Moreover, our results from other in vitro acquired resistant
cell lines indicated that regardless of the PTEN status, p-AKT could
be induced by vemurafenib or AZD6244 treatment. These findings
indicate that alterations in both MAPK and AKT pathways can be
the cause of resistance to vemurafenib and induction of p-AKT in
resistant melanoma cell lines is rather a more general phenomenon
and not solely limited to PTEN mutant cell lines.
There is clear evidence of multiple levels of cross-talk between
MAPK and PI3K/AKT pathways, and it has been shown that
ERK can be phosphorylated by the AKT pathway (Figure S4)
[19,25]. Therefore, it is likely that treatments to inhibit alternative
survival signaling in melanoma cells resistant to MAPK inhibitors
will require co-inhibition of the PI3K/AKT pathway. The concept
of simultaneous inhibition of the MAPK and the PI3K/AKT/
mTOR pathways has been widely considered to treat altered
oncogenic signals [7,18,20,26], and at least one clinical trial
combining a MEK inhibitor with an AKT inhibitor is currently
underway (NCT01021748). Given the frequent cross-talk and
feedback regulation between both pathways we explored the effects
of vemurafenib or AZD6244 on p-AKT and its downstream factors
as the key signaling molecules in cells with primary or acquired
resistance to vemurafenib. Our approach was also based on the
evidence that cells with resistance to PLX4720, an analogue of
vemurafenib, have a MEK-independent survival drive that can be
blocked by inhibitors of the PI3K/AKT/mTOR pathway [25]. In
addition, in cell lines with acquired resistance to BRAF inhibitors
through upregulation of IGF1R, resistance can be inhibited by the
co-administration of a combination of a MEK and a PI3K inhibitor
[14]. Indeed our experiments demonstrated a differential effect on
the AKT/mTOR/S6K pathway in vemurafenib-sensitive and -
resistant cells both when exposed to vemurafenib or AZD6244. The
most profound effect was the persistence of p-p70 S6K1 in cross-
resistant cell lines treated with either drug, but it was particularly
more evident with the MEK inhibitor AZD6244. Genetic inhibition
of both p70 S6K1 and S6K2 with siRNAs showed additive effects
with either of the drugs to further decrease the phosphorylation of
the downstream protein S6. It should be noted that S6 can be
phosphorylated at Ser235 by p-ERK as well. Therefore, changes in
phophorylation of S6 can be the result of alterations in activity of p-
ERK or p-P70 S6K1 or both, and that can be the reason for the lack
of direct correlation between phosphorylation of S6K and S6 in our
pharmacological inhibition studies.
In this study, siRNA knockdown of RICTOR decreased p-AKT
Ser473 and also exhibited additive effects with vemurafenib or
AZD6244 in further decreasing p-S6 and p-4EB-P1. These data
suggest that S6 and 4EB-P1 are also potential cross-talk points
between the AKT and MAPK pathways. Therefore, at least in this
case, inhibition of both pathways is necessary to overcome the
resistance to vemurafenib and AZD6244. Moreover, the inhibitory
effect of RICTOR knockdown on growth of resistant cells suggests
that activation of AKT by mTORC2 feedback may play a role in
maintenance or even induction of cell growth and therefore can be
one of the causes of resistance to MAPK pathway inhibitors. AKT
activation by the feedback mechanism could be the cause of
growth inducing effect of vemurafenib in resistant cell lines. This
feed back mechanism occurs through the induction of mTORC2,
which contains RICTOR, and causes higher levels of S473 p-
AKT. It should be mentioned that the ability of a combination of
MAPK pathway and AKT/mTORC inhibitors to reverse
resistance to single agent MAPK inhibitors was not absolute and
inefficient for some of the cell lines with primary and acquired
cross-resistance to vemurafenib and AZD6244. Growth inhibition
assays indicated that combinations of chemical inhibitors of
MAPK and AKT pathways can decrease growth rates of some of
the vemurafenib resistant cell lines. However these decrease in
growth rates of resistant cell lines were not accompanied by the
induction of apoptosis in these cell lines, particularly when
vemurafenib alone or in combination was used. In the resistant
cell lines, inhibition of MEK by AZD6244 could cause some
induction cleaved caspase 3 in comparison to the vehicle treated
samples. However, levels of cleaved caspase 3 were not increased
further by the combination of AZD6244 and inhibitors of AKT
pathway. This discrepancy between the growth and apoptosis
assays perhaps indicate that these drug combinations may inhibit
the growth by mechanisms other than apoptosis or through the
ways which do not cause the induction of cleaved caspase 3.
Other investigators have provided convincing evidence that the
effects of targeted inhibitors on melanoma cell lines is different in 2-
dimension and 3-dimension models [27], with higher resistance to
BRAF inhibitors in 3 dimension models mediated by the PI3K/
AKT pathway [28]. This was not tested in our studies, and may
further underscore the importance of co-targeting both the MAPK
and the PI3K/AKT/mTOR pathways for more profound
antitumor effects in cells with acquired resistance to single agent
BRAF inhibitors. Another possibility to expand on our studies
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would be the testing of siRNA or an isoform-specific inhibitor of
AKT3, which has been previously described to be important in
melanoma [29]. The fact that the particular inhibitor used by us
(which preferentially blocks AKT1 and AKT2, but at higher
concentrations also blocks AKT3) had synergistic effects with
vemurafenib or AZD6244 in several cells with cross-resistance to
either single agent underscores the promise of co-targeting both
pathways as means to treat acquired resistance to BRAF inhibitors.
In conclusion, our data suggest that single agent MEK inhibitor
has low activity in vemurafenib-resistant melanoma and perhaps
restricted to a subset of cases with secondary oncogenic mutations
in NRAS. However, upon progression the addition of an AKT or
an mTOR inhibitor to the continued therapy with vemurafenib,
or switching to a combination of a MEK inhibitor plus an AKT or
an mTOR inhibitor, may provide additional inhibitory activities.
Our data strengthens the results from other groups that have
previously demonstrated the superior antitumor activity of
combining MAPK and PI3K/AKT/mTOR pathway inhibitors
in BRAFV600E mutant cell lines [14,24,30], by testing this concept
in isogenic pairs of sensitive and acquired resistant cell lines, and in
cell lines established directly from patients progressing after a
response on vemurafenib. Therefore, the elucidation of the
molecular mechanisms that result in primary or acquired
resistance to vemurafenib and sensitivity to combined MAPK
and AKT/mTOR pathway inhibition, would provide useful
biomarkers to rationally choose the most appropriate therapy in
BRAFV600E mutant melanomas resistant to vemurafenib.
Supporting Information
Figure S1 Examples of viability assays at different
concentrations of vemurafenib or AZD6244. Effects of
vemurafenib or AZD6244 on cell growth and viability using an
MTS assay was determined in the previously established cell line
M229 and its in vitro acquired resistance M229-AR9 subline.
(TIF)
Figure S2 Effects of RAPTOR knockdown by siRNAs in
combination with either vemurafenib or AZD6244. The
efficiency of siRNA knockdowns and its effect on downstream
signaling determined by Western blot analysis of protein lysates (a).
M238 parental (b) and M238-AR2 resistant subline (c) were
transfected with RAPTOR siRNAs and cultured in increasing
concentrations of vemurafenib or AZD6244. The effect of raptor
knockdown on resistance and growth inhibition was analyzed after
120 hours by an MTS assay. D in each graph refers to the un-
transfected untreated cells and is used as the 100% reference point
for all the conditions in the assays.
(TIF)
Figure S3 Cleaved caspase-3 in sensitive and adaptive
resistant cell lines treated with vemurafenib, AZD6244,
rapamycin, AKTi. Cell lines were treated by the solvent
(DMSO), 2 mM of vemurafenib, AZD6244, AKTi or 10 nM of
rapamycin for 48 hours. Each sample was analyzed by Western
blotting using a cleaved caspase-3 (CC3) specific antibody.
(TIF)
Figure S4 Diagram of pathways and possible cross-talk
points involved in survival and resistance of melanoma
cell lines.
(TIF)
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